TABLE 3.

Quantitative results of HB-HTA of MP versus SCS (information is presented for items where qualitative information was available).

Dimension	Available information
Clinical	• No increased complication rate (15, 24, 30, 32, 35, 37)
	• Prolonged total graft preservation time (15, 35)
	• 10–50% reduced risk for EAD (7, 17, 24, 30, 36, 37, 41, 47)
	• 7–15% less IRI (7, 17, 28, 32, 39, 42)
	• 7–50% fewer IBC (7, 15, 17, 24, 30, 31, 36, 37, 47)
	• Comparable (22, 24) or improved 1-year graft (30, 47) and patient survival (30, 35)
	• Up to a 50% lower discard rate (31, 35, 43)
Economic(al)	• Increased costs [per-run cost of 18,593.02 $Can (13); per-patient increase of 9,341£ (20)]
	• Theoretically improved cost-effectiveness and cost utility (21)
	• Increased use of economic resources (13, 21)
Ethical	• Anecdotal single reports of MP-related adverse events (37)
Social	• No difference in length of hospital stay (15, 24, 30)

Note. EAD, early allograft dysfunction; HB-HTA, hospital-based health technology assessment; HT, health technology; HTA, health technology assessment; IBC, ischemic biliary complications; IRI, ischemia reperfusion injury; MP, machine perfusion; SCS, static cold storage.